Glucagon-Like Peptides

"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

Descriptor ID	D004763
MeSH Number(s)	D06.472.317.469.500
Concept/Terms	Glucagon-Like Peptides Glucagon-Like Peptides Glucagon Like Peptides Glucagon-Like Polypeptides Glucagon Like Polypeptides Enteroglucagons Enteroglucagons Gut Glucagon Enteroglucagon

Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Gastrointestinal Hormones [D06.472.317]
Proglucagon [D06.472.317.469]
Glucagon-Like Peptides [D06.472.317.469.500]

Below are MeSH descriptors whose meaning is related to "Glucagon-Like Peptides".

Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.

Bar chart showing 14 publications over 10 distinct years, with a maximum of 4 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2004	0	1	1
2006	1	0	1
2012	0	1	1
2017	1	0	1
2020	1	0	1
2021	0	1	1
2022	0	4	4
2024	2	0	2
2025	1	0	1

Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.

Cai CX, Hribar M, Baxter S, Goetz K, Swaminathan SS, Flowers A, Brown EN, Toy B, Xu B, Chen J, Chen A, Wang S, Lee C, Leng T, Ehrlich JR, Barkmeier A, Armbrust KR, Boland MV, Dorr D, Boyce D, Alshammari T, Swerdel J, Suchard MA, Schuemie M, Bu F, Sena AG, Hripcsak G, Nishimura A, Nagy P, Falconer T, DuVall SL, Matheny M, Viernes B, O'Brien W, Zhang L, Martin B, Westlund E, Mathioudakis N, Fan R, Wilcox A, Lai A, Stocking JC, Takkouche S, Lee LH, Xie Y, Humes I, McCoy DB, Adibuzzaman M, Areaux RG, Rojas-Carabali W, Brash J, Lee DA, Weiskopf NG, Mawn L, Agrawal R, Morgan-Cooper H, Desai P, Ryan PB. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025 04 01; 143(4):304-314.

View in: PubMed
Harrison DB, Phillips AL, Tansey JB, Clarke TJ, Wood CB, Nedzi L, Schwartz DL, Makowski L, Hayes DN, Newman G, Gleysteen JP. Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug. Laryngoscope. 2025 02; 135(2):741-743.

View in: PubMed
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.

View in: PubMed
Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022 12; 28(15 Suppl):S297-S306.

View in: PubMed
Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022 Jan; 134(sup1):18-27.

View in: PubMed
Kyrillos JV, Skolnik NS, Mukhopadhyay B, Pennings N. Integrating semaglutide into obesity management - a primary care perspective. Postgrad Med. 2022 01; 134(sup1):37-49.

View in: PubMed
Kyrillos JV, O'Neil PM, Wharton S. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgrad Med. 2022 01; 134(sup1):1-4.

View in: PubMed
Zupa MF, Codario RA, Smith KJ. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. J Comp Eff Res. 2021 10; 10(15):1133-1141.

View in: PubMed
Morales J, Shubrook JH, Skolnik N. Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgrad Med. 2020 Nov; 132(8):687-696.

View in: PubMed
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 10 17; 318(15):1460-1470.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement